The common human epilepsies are associated with distinct patterns of reduced cortical thickness, detectable on neuroimaging, with important clinical consequences. To explore underlying mechanisms, we layered MRI-based cortical structural maps from a large-scale epilepsy neuroimaging study onto highly spatially-resolved human brain gene expression data, identifying >2,500 genes overexpressed in regions of reduced cortical thickness, compared to relatively-protected regions. The resulting set of differentially-expressed genes shows enrichment for microglial markers, and in particular, activated microglial states.
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Introduction
Significant progress is being made in understanding disease processes in the epilepsies.
Many genetic variants causing or associated with rare and common epilepsies have been reported 1, 2 , with discovery continuing apace 3 . Numerous direct structural causes of epilepsy have been revealed by brain magnetic resonance imaging (MRI), since its widespread implementation in the period immediately preceding the extensive application of genetics.
Several structural abnormalities are now themselves known to have a genetic basis 4 . As a result, the proportion of causally-explicable epilepsies is growing rapidly. Conversely, the mechanisms whereby these identified causes promote epileptogenesis and seizures remain obscure for most human epilepsies. Moreover, beyond causation and epileptogenesis, the epilepsies involve many other processes: some lead to clinically-apparent consequences, such as developmental delay or memory dysfunction, whereas others, without necessarily obvious symptoms, may be detected only on investigation -cerebellar atrophy is one example. The natural history of any given epilepsy need not be a single linear dynamic from causation to a unique, predictable, final outcome: for example, the epilepsies are associated with shortened longevity (even if seizures stop) 5 and increased risk of particular comorbidities 6 . Known causes per se may not explain all the observed outcomes, suggesting that many epilepsies could be conceptualised as intricate matrices of causation, processes and outcomes 7 , with complex inter-dependencies, such as a likely link between reduction in cortical thickness and disease duration 8 .
Through the ENIGMA-Epilepsy consortium, we recently showed that across a wide range of common human epilepsies, which are known to have both distinct and shared genetic architecture 2, 3, 9, 10 , there are also shared, pan-syndrome, and distinct, syndrome-specific, regional patterns of altered cortical thickness and altered subcortical grey matter volumes 8 .
The causes of the structural changes in these epilepsies are not known. The findings 8 suggest structural losses may reflect an initial insult, subsequent epileptogenesis or progressive neurodegeneration, or some combination, and indicate that the epilepsies cannot necessarily be considered entirely benign at the structural level. We sought to identify processes underlying the structural findings.
Human neurological disease biology has been successfully revealed using powerful combinations of brain MRI findings, regionalised brain-specific gene expression and gene co-expression network datasets, in systems biology approaches implicating candidate genes [11] [12] [13] [14] [15] [16] [17] [18] [19] . Here, we used the findings from the ENIGMA-Epilepsy study to direct interrogation for regionalised gene expression changes, which in turn identified candidate genes which might underlie thickness or volume reductions across the studied epilepsy syndromes. Gene expression is itself largely driven by underlying constitutional genetic variation. We therefore hypothesised that this approach could pick out disease mechanisms causing the observed structural changes. We then tested whether the postulated mechanisms were identifiable from epilepsy susceptibility or treatment-response genomewide association studies and further explored the findings with a series of additional experiments in both human and animal tissues. We demonstrate experimentally that depletion of the cell type, microglia, most strongly implicated by the systems biology approach can successfully avert cortical thinning. Together, the results point to the potential for prevention of the widespread, but largely unstudied, reduction in cortical thickness that accompanies common human epilepsies.
Results
Cortical regions at most risk of reduced thickness in individuals with common forms of epilepsy are characterised by higher expression of over 2500 genes
Through the ENIGMA-Epilepsy consortium, we recently showed that across a wide range of common epilepsies, there are distinctive regional patterns of altered cortical thickness and altered subcortical grey matter volumes 8 .
To identify the molecular basis of this regional vulnerability in the broad spectrum of epilepsies, we focused our analyses on the shared pan-syndrome cortical findings and leveraged data from the Allen Institute for Brain Science (AIBS) healthy human brain gene expression atlas ( Figure 1 ). We chose to study all the epilepsies as a group not only because of the general importance of pan-syndrome cortical findings, but because these structural changes were most likely to reveal the conditionspecific, as opposed to syndrome-specific, processes driving the selective vulnerability of cortical regions. We hypothesised that matching patterns of regional cortical vulnerability to reduced thickness with patterns of gene expression differences across the human cortex would point to possible mechanisms underlying the brain structural changes, and then tested the emerging putative mechanisms in an experimental model. Genes associated with reduced cortical thickness in the common epilepsies are significantly enriched for microglial markers Although all cortical regions are similar in structure and cellular composition, there are regional differences, which are detectable within bulk gene expression data [20] [21] [22] [23] . We determined whether the genes differentially expressed in vulnerable, as compared to relatively protected, cortical regions could be used to infer cell type(s) involved in mediating cortical thinning ( Figure 1 ). First, we made use of cell-specific gene expression data generated using bulk mouse cortex, and covering the major cellular classes, namely astrocytes, endothelial cells, microglia, myelinating oligodendrocytes, newly-formed oligodendrocytes, oligodendrocyte precursor cells and neurons 24 . We used murine data initially, because of its more robust nature, unconfounded by disease effects. Using this approach, we identified a significant enrichment of sets of microglial-marking genes amongst those genes overexpressed in vulnerable cortex (PFDR=1.01x10 -26 ; Supplementary Table 2) .
Conversely, those genes overexpressed in relatively protected cortical regions were enriched for sets of neuron-specific genes (PFDR=2.34x10 -6 ; Supplementary Table 3 Table 4) .
Since evidence suggests species differences in cell-specific expression 26 , we extended these findings using human-derived data 26 . Although these human data are more prone to confounding errors due to the small number of tissue samples used and the fact that cortex samples were obtained from surgical resections for a range of brain diseases including epilepsy (18 of 22), we were able to confidently replicate our major findings. In relatively protected areas, we confirmed enrichment of a neuron marker gene set derived from human tissue (PFDR=2.77x10 -43 ; Supplementary Table 3) . We also identified a highly significant enrichment of microglia-marking genes amongst those overexpressed in vulnerable cortical regions (PFDR=6.82x10 -54 ; Supplementary Table 2) . Together, these analyses from mouse and human data suggest that vulnerability to reduced cortical thickness is likely to be mediated at least partly through microglia-specific processes.
Evidence for selected processes and microglial signatures amongst genes associated with reduced cortical thickness in the common epilepsies Moving beyond individual genes and cell types, we next investigated the biological processes that could underpin regional differences in vulnerability to reduced cortical thickness in epilepsy. In the first instance we investigated differentially expressed genes for evidence of Gene Ontology, KEGG and REACTOME pathway enrichment. Amongst genes overexpressed in relatively protected cortical regions, the most significant terms we identified related to synaptic function (GO: Synapse, PFDR=1.60x10 -7 ; GO: Neuronal postsynaptic density, PFDR=7.27x10 -5 ; Supplementary ; Supplementary Table   6 ).
Since microglia can exist in a range of activation states within the context of epilepsy 27 , we sought to integrate the cell-specific and pathway analyses already performed, to identify the microglial cell states of greatest importance in reduced cortical thickness. We collated gene signatures for distinct microglial states from the existing literature and also inferred signatures of microglial state through co-expression network analyses (see Online Methods).
While there were significant overlaps in gene membership across the 16 microglial signatures used (Supplementary Figure 1) , each of the gene lists were distinct. We identified a significant enrichment for 10 of the 16 signatures with genes overexpressed in vulnerable cortex. This included the microglial signature generated by Srivastava and colleagues 28 , which was positively correlated with seizure frequency in a mouse model of chronic epilepsy (PFDR=4.81x10 -17 ; Supplementary [29] [30] [31] . However, the data do not exclude contributions from other microglial states at early stages of epilepsy in humans, including during epileptogenesis.
Genetic evidence in support of immune activation as a modifying, but not causal, factor in common epilepsies
Region-specific reduced cortical thickness across the common epilepsies was correlated with disease duration and age of onset of epilepsy 8 . Given that the analyses described above suggest the importance of microglia responses in vulnerability to reduced cortical thickness, we predicted that genetic variants affecting microglial responses would also impact upon the severity of epilepsy. While no microglial eQTL data set exists to date, eQTL analyses have been performed using monocytes at rest, and also monocytes treated with IFN-γ or lipopolysaccharide (LPS) 32 . We postulated that these eQTLs would be enriched for heritability of risk loci for epilepsy that is drug-resistant (one surrogate for disease severity)
but not for epilepsy per se. To investigate this, we used GWAS data on epilepsy susceptibility 2 and separate GWAS data on the phenotype of drug-resistant epilepsy from the EpiPGX consortium (www.epipgx.eu). Using LD score regression, we sought enrichment in heritability for these phenotypes within state-specific monocyte eQTLs 32 . We found no significant enrichment in the heritability of epilepsy in this form of annotation, suggesting that susceptibility to common epilepsies is less likely to be driven by immune processes (Table   1 ). However, eQTLs regulating the response to IFN-γ were highly enriched for drug-resistant epilepsy vs drug-responsive epilepsy loci (P=0.00045; PFDR=0.0095, Table 1 ). This result was particularly striking given the small size of this GWAS (2423 drug-resistant cases vs 1626 drug-responsive cases). Thus, we provide genetic evidence in support of microglialmediated responses as a modifying factor in severity of epilepsy, but not its susceptibility. Experimental evidence in support of microglial activation as a modifying factor for cortical thickness in a mouse model of epilepsy
To provide proof-of-concept evidence causally linking microglia activation to cortical thinning,
we used a mouse model of acquired epilepsy where convulsive seizures originate and spread in the limbic system, and also involve the neocortex. [33] [34] [35] [36] This model mimics features of mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE), with neuronal damage also observed in extrahippocampal areas 33, 34, 36 , as also shown in human MTLE in the ENIGMA-Epilepsy study 8 . 
Discussion
The epilepsies are complex conditions with multiple facets including various causes, differing responses to treatment, and unpredictable outcomes. Most attention has been paid to causation and processes of epileptogenesis across the broad constituent spectrum of syndromes. In contrast, disease progression has not been a primary focus of research even though for some rare epilepsies (the developmental and epileptic encephalopathies, DEE), the window of opportunity to ameliorate disease may be open for longer than expected, as disrupted patterns of gene expression last into adulthood 18 . Here, we show that across the broad spectrum of the more common epilepsies (specifically excluding DEE), patterns of gene expression spatially correlated with reduced cortical thickness implicate neuroinflammatory processes, and, particularly, microglial activation, as contributors to the underlying cause of reduction in cortical thickness. We show that this molecular signature of neuroinflammation significantly overlaps with a gene set already causally linked to seizure frequency in a mouse model of chronic epilepsy 28 . Further, our data add new evidence
showing that microglial activation is associated with at least some of the structural changes seen in brain areas involved in seizure circuitry, in that microglial depletion can directly prevent associated cortical thinning.
We tested the hypothesis that microglial/monocyte activation is a key modulator of the severity of epilepsy using both genetic and functional approaches. We used the availability of GWAS data for resistance to anti-epileptic drug treatment, a marker of disease severity, to investigate enrichment in heritability at genetic loci already known to influence the expression of genes involved in monocyte activation. We note this analysis assumes a high degree of similarity in the genetics of gene expression in monocytes and microglia. We find a highly significant enrichment in the heritability of epilepsy severity amongst these immunomodulatory loci, despite the absence of a significant enrichment for heritability of epilepsy per se. Finally, in keeping with these observations, experimental microglial depletion timed to coincide with a period of epileptogenesis in a murine model can prevent regionalised cortical thinning, but does not influence the eventual development of seizures themselves in our model. Data from the experimental model also demonstrate that the cortical thinning is at least partly due to reduced neuronal cell density and average neuronal size: reduction of neuronal density can be prevented by appropriately-timed microglial depletion (neuronal size changes were not rescued, which may explain the observation that entorhinal volume changes are not completely prevented by microglial depletion). We, and others [37] [38] [39] [40] [41] , find activated, Iba1 + -microglia are present in excess in brain tissue from people with epilepsy, compared to brain tissue from healthy controls, providing evidence for translation to human epilepsies of our assertions from the experimental model data.
Together, these findings separate important processes occurring in the course of the epilepsies, and incriminate potentially modifiable microglial activation states in the hitherto largely-ignored feature of cortical thinning in the common human epilepsies. Our results also suggest other factors are likely to be involved.
Importantly, we note that the clue to the possible role for microglial activation in cortical thinning came from a cross-sectional study of chronic human epilepsy: although reduced cortical thickness correlated with disease duration 8 , we could not distinguish whether the structural difference had developed at disease onset (e.g. with causation), during epileptogenesis, during the course of the disease, or a combination of these epochs. Our multimodal data, and especially the experimental model results, allow us to begin to address this question. The model relates to early processes in epileptogenesis, and show a separation for microglial roles in cortical thinning and seizure occurrence, whilst data from another model relates to the chronic disease state, and shows an effect of microglial manipulation on seizure frequency in that chronic state 28 (cortical thinning was not assessed in that model). The models and data are not directly compatible, and we cannot test hypotheses arising from the chronic model in data from ENIGMA-Epilepsy. However, taken together, the data suggest microglia may have multiple modifying roles during epileptogenesis and progression of disease across common human epilepsies, though we find no evidence that they contribute to the actual occurrence of these common forms of epilepsy (from either our human or murine data). That seizure frequency and cortical thinning may be separable processes adds to important epidemiological evidence that seizure frequency is not the only contributor to morbidity in people with a history of epilepsy. Considering the complex relationship between inflammation and epilepsy, it is noteworthy that despite the growing evidence for neuroinflammation as a modulator of epilepsy, overt neuroinflammation is considered causal in a very few, rare, severe human epilepsies.
Rasmussen's encephalitis is a severe drug-resistant epilepsy characterised by progressive loss of cerebral substrate, in which astrogliosis and T-lymphocyte infiltration are central features, with IFN-γ and granzyme B overactivity and evidence of efficacy of α4 integrin blockade 44 . Microglial activation is also seen in Rasmussen's encephalitis, and in tissue from epilepsies due to hippocampal sclerosis and mesial temporal lobe sclerosis, focal cortical dysplasia (FCD) and tuberous sclerosis [37] [38] [39] [40] [41] . The latter two conditions are known to have genetic, rather than inflammatory, causes, but the extent of microglial activation in the chronic disease phase correlates with seizure frequency and disease duration in these studies 37, 41 , pointing again to distinction between processes related to the initial cause and others manifest during active disease. Importantly, resected human brain tissue is only available from a few cases of a few types of epilepsies (mostly surgical specimens from MTLE and FCD 45 ), so that it is impossible to otherwise evaluate the role of microglia using neuropathological data in the majority of common human epilepsies, from which brain tissue cannot be obtained in life. Brain imaging in animal models using a label (TSPO) for 20 microglial activation shows dynamic upregulation during epileptogenesis, with persistent, although declining, activity in the chronic phase and correlation with spontaneous seizures 46 ; in chronic human TLE, there is increased TSPO binding ipsilateral and contralateral to seizure foci 47 .
Using immunolabelling, we demonstrate that there is over-representation of activated microglia in human and experimental brain tissue, compared to controls. However, neither TSPO imaging nor neuropathological study is realistically applicable to large numbers of people with epilepsy, whilst MRI is. We propose, using MRI-derived patterns and correlation with gene expression, that microglial-associated neuroinflammation drives the important, but as yet largely neglected, phenotype of cortical thinning in a broad swathe of common human epilepsies. Subsequent experimental intervention in an animal model suggests that early manipulation of microglia has the capacity to rescue disease-related cortical thinning, opening up new areas for attention and treatment in common human epilepsies.
Our results point to important roles for neuroinflammation and potentially specific molecular actors, such as IFN-γ. However, the diversity of microglial states and functions, and the complex, dynamic, interactions between neurons, astroglia and microglia, that at the very least can promote epileptogenesis 27 have yet to be fully resolved. Our key observation is that microglial activation is not a rare phenomenon in the epilepsies, but is likely to be central across the breadth of types of epilepsy. Not only does this deepen understanding and show that some disease processes and progression in epilepsy may be independent of cause, but also offers new avenues for treatment and disease modification. Manipulation of microglial activity may not only address the common phenomenon of treatment resistance 28 , but may also prevent irreversible loss of brain substance.
Figures Figure 1. Analysis overview
Panel a: Cortical samples of the AIBS dataset were marked as "vulnerable" or "relatively protected" based on whether they were located in a brain region that showed significant reduction in cortical thickness or not, respectively, in a large imaging study 8 . Differential gene expression analysis between the two groups produced the genetic risk signature of reduced cortical thickness in epilepsy.
Panel b: Significantly differently expressed genes with higher expression in "vulnerable"
regions were found to be enriched for marker genes for microglia as well as immune activation related pathways. 29 Figure 1 30 Figure 2 31 Figure 3 32 Figure 4 
